Nutra Pharma, Inc. (PinkSheets: NPHC)

The NurtraPharma Corporation is a diverse biotechnology company that offers an array of services within the biotech industry. Specifically, the company is dedicated to developing proprietary therapeutic protein products as well as rapid diagnostic tests to identify infectious diseases. The company also specializes in researching applications for neurological, immunological and autoimmune conditions.

Currently, the company has two leading drug candidates they are hoping to implement into the billion-dollar biologics industry. The first candidate (RPI-MN) is being developed as the first treatment of HIV. The company is also developing a drug for the treatment of Multiple Sclerosis, which is named RPI-78M. Both drugs have not been shown to have adverse side effects in humans or animals.

The companies’ Cobroxin product is the first over-the-counter pain reliever that treats Stage 2 chronic pains. The drug is non-narcotic, non-addictive and all natural. According to the American Pain Foundation, over 25 million Americans visit the doctor each year for acute pain problems, making the products market potential enormous.

NutraPharma subsidiary company, ReceptoPharm, is a leader in offering services for small and start-up biotech companies. The subsidiary offers pathways to the development, production, and supply of clinical material for Phase I and II studies.

NutraPharama also specializes in biotechnology sales and marketing through another subsidiary named Designer Diagnostics. The company founded the sales of diagnostic test kits for infectious diseases. These test kits are highly affordable and very efficient.

Overall, the NutraPharma Corp. is a diverse leader in the biotechnology industry. The stock continues to make new highs for the year and with so much potential for growth, we are very bullish on the stock for the upcoming year, with a target price of $2.00 per share for 2010.